Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Predicted T-Cell and B-Cell Epitopes of NIS: Where Do Sjögren's Syndrome and Hashimoto's Thyroiditis Converge?

International journal of molecular sciences·2026

Same author

Unlocking the Power of the Mediterranean Diet: Two in One-Dual Benefits for Rheumatic and Thyroid Autoimmune Diseases.

Nutrients·2025

Same author

The Effect of Therapeutic Exercise and Local Cryotherapy on Lower Limb Enthesitis in Non-Radiographic Axial Spondyloarthritis: A Case Report.

Journal of personalized medicine·2024

Same author

Metaproteomics reveals diet-induced changes in gut microbiome function according to Crohn's disease location.

Microbiome·2024

Same author

Pediatric migraine is characterized by traits of ecological and metabolic dysbiosis and inflammation.

The journal of headache and pain·2024

Same author

Sequence Alignment between <i>TRIM33</i> Gene and Human Noncoding RNAs: A Potential Explanation for Paraneoplastic Dermatomyositis.

Journal of personalized medicine·2024

Search research articles

Related Experiment Video

Updated: Sep 18, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Baicalin as a potential candidate for treating systemic sclerosis.

Giada Cimino¹, Federica Rapisarda², Rossella Talotta³

¹Nursing Degree School, University of Messina, Messina, Italy.

Inflammopharmacology

|June 23, 2025

Summary

This summary is machine-generated.

Baicalin, a natural compound, shows potential for treating systemic sclerosis (SSc) by addressing its core issues: immune dysfunction, vasculopathy, and fibrosis. Further clinical studies are needed to confirm its efficacy and safety in SSc patients.

Keywords:

Alternative medicine Autoimmunity Baicalin Endothelial dysfunction Fibrosis Systemic sclerosis

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Related Experiment Videos

Last Updated: Sep 18, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Area of Science:

Immunology
Rheumatology
Pharmacology

Background:

Systemic sclerosis (SSc) is a complex connective tissue disease involving immune cell activation, endothelial dysfunction, and fibrosis.
Current SSc treatments are limited due to incompletely understood pathogenesis.
Baicalin, a flavonoid from Scutellaria baicalensis, has demonstrated efficacy in various preclinical disease models.

Purpose of the Study:

To review the potential of baicalin in managing SSc.
To explore baicalin's mechanisms against SSc's key pathological features: vasculopathy, immune dysfunction, and fibrosis.

Main Methods:

Narrative review of existing literature.
Analysis of baicalin's known pharmacological actions.
Assessment of relevance to SSc pathogenesis.

Main Results:

Baicalin exhibits multiple mechanisms, including TLR4 antagonism, TGF-β/Smad3 pathway inhibition, and antioxidant effects.
These properties align with counteracting SSc's pathogenic triad.
Preclinical data suggests potential benefits in related conditions.

Conclusions:

Baicalin presents a promising therapeutic candidate for SSc based on its multifaceted pharmacological profile.
Its potential to address vasculopathy, immune dysfunction, and fibrosis warrants further investigation.
Clinical trials are essential to establish baicalin's efficacy and safety in SSc patients.